CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
Vous n'êtes pas connecté
CRANFORD, N.J., Aug. 8, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) ("Citius", "Citius Pharma"), announced today that the U.S. Food and Drug Administration (FDA) has approved Lymphir (denileukin diftitox-cxdl), a novel...
CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell...
KalVista announces FDA acceptance of New Drug Application for sebetralstat for oral on-demand treatment of hereditary angioedema KalVista...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--Sep. 3, 2024-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the U.S....
PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...
PLAINSBORO, N.J., Aug. 30, 2024 /PRNewswire/ -- Today, The Lancet published a new pooled, participant-level analysis of patients with heart failure...
Researchers at The University of Queensland are developing a comprehensive paediatric immune cell ‘atlas’ to aid in the diagnosis and treatment of...
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration...
GAITHERSBURG, Md., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration...
Bora Pharmaceuticals Co., Ltd. (Bora), a leading global pharmaceutical manufacturer, announced that its board of directors has approved a strategic...